Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.25 USD | +2.87% | -5.57% | +59.15% |
Apr. 19 | Sector Update: Health Care Stocks Steady Pre-Bell Friday | MT |
Apr. 19 | Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares | MT |
Financials (USD)
Sales 2024 * | 6.82M | Sales 2025 * | 5.17M | Capitalization | 1.25B |
---|---|---|---|---|---|
Net income 2024 * | -169M | Net income 2025 * | -167M | EV / Sales 2024 * | 90.4 x |
Net cash position 2024 * | 638M | Net cash position 2025 * | 333M | EV / Sales 2025 * | 178 x |
P/E ratio 2024 * |
-9.73
x | P/E ratio 2025 * |
-11.9
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.45% |
Latest transcript on Spyre Therapeutics, Inc.
1 day | +2.87% | ||
1 week | -5.57% | ||
Current month | -9.70% | ||
1 month | -16.87% | ||
3 months | +25.09% | ||
6 months | +175.99% | ||
Current year | +59.15% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Scott Burrows
DFI | Director of Finance/CFO | 47 | 23-08-31 |
Brian Connolly
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tomas Kiselak
BRD | Director/Board Member | 38 | 23-06-21 |
Russell Cox
CHM | Chairman | 60 | 15-05-31 |
Jeffrey Albers
BRD | Director/Board Member | 52 | Nov. 26 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 34.25 | +2.87% | 201,520 |
24-04-22 | 33.3 | +2.73% | 261,723 |
24-04-19 | 32.41 | -8.91% | 395,420 |
24-04-18 | 35.58 | +3.70% | 415,289 |
24-04-17 | 34.31 | -5.40% | 548,013 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.15% | 1.25B | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+2.91% | 22.19B | |
-16.16% | 21.33B | |
-7.19% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- SYRE Stock